Company Overview

biote Corp. is a U.S.-based healthcare company focused on preventive health care and hormone optimization therapies, primarily through bioidentical hormone replacement therapy (BHRT). The company operates in the wellness and preventive medicine sectors and provides a practice-building platform for physicians and clinicians that includes hormone therapy training, diagnostic support, nutraceutical supplements, and patient management tools. biote’s primary revenue drivers include sales of hormone optimization products, dietary supplements, and recurring procedure-related revenue generated through its network of certified practitioners.

The company’s business model centers on enabling medical providers to offer personalized hormone therapy solutions, primarily using subcutaneous pellet therapy designed to deliver hormones consistently over time. biote serves patients seeking treatment for age-related hormonal imbalance and wellness-related conditions, with a significant concentration in the U.S. cash-pay health care market. Originally established as a privately held company, biote later became publicly traded through a business combination with a special purpose acquisition company (SPAC), resulting in its listing on Nasdaq under the ticker BTMD. Its strategic positioning is tied to its practitioner network, recurring patient relationships, and integrated training-and-product ecosystem.

Business Operations

biote generates revenue primarily through its Practitioner Services platform and sales of hormone-related therapies and wellness supplements. The company trains and certifies medical practitioners in the use of its BHRT protocols and provides ongoing support services, including clinical education, marketing assistance, software tools, and access to proprietary treatment methods. Revenue is also derived from nutraceutical products sold under the company’s wellness portfolio and from procedural utilization by participating clinics.

Operations are predominantly concentrated in the United States, where biote maintains a broad network of affiliated practitioners and clinics. The company’s operational infrastructure includes physician training programs, patient management technologies, and supply chain relationships supporting pellet manufacturing and supplement distribution. biote has also developed relationships with independent medical providers and wellness-focused clinics to expand patient access. Public filings and investor materials identify technology-enabled practice support and recurring patient engagement as central components of the company’s operating model.

Strategic Position & Investments

biote’s strategic direction emphasizes expansion of its practitioner network, increased patient penetration within preventive health care markets, and growth in recurring wellness-related revenue streams. The company has invested in digital capabilities, provider education programs, and product portfolio expansion to strengthen retention among affiliated clinicians. Management has also highlighted opportunities to increase adoption of hormone optimization therapies among aging populations and consumers seeking personalized health solutions.

The company has pursued selective acquisitions and partnerships aimed at strengthening operational capabilities and broadening its wellness offerings. biote has also focused on expanding its nutraceutical and dietary supplement portfolio to complement its hormone therapy business. Its strategy reflects broader trends in personalized medicine, longevity-focused care, and cash-pay wellness services. Public disclosures indicate ongoing investment in clinical education, patient engagement technologies, and practitioner support systems as competitive differentiators within the hormone optimization market.

Geographic Footprint

biote is headquartered in Irving, Texas, and its primary market presence is within the United States. The company supports a nationwide network of clinics and certified practitioners operating across multiple states, with concentration in suburban and metropolitan health care markets. Its operations are primarily domestic, reflecting regulatory and reimbursement dynamics associated with U.S. preventive and wellness care.

While biote’s direct international operational footprint appears limited based on publicly available disclosures, the company participates in broader health and wellness trends that have global relevance. Its influence outside the U.S. largely stems from practitioner education, hormone optimization methodologies, and exposure to international wellness industry developments rather than extensive overseas operations. Data regarding material international subsidiaries or large-scale foreign revenue contributions is inconclusive based on available public sources.

Leadership & Governance

biote is led by an executive team with backgrounds in health care services, medical technology, finance, and operational management. The company’s leadership strategy emphasizes scalable practitioner relationships, recurring wellness revenue, and expansion within preventive medicine markets. Governance practices are shaped by public company reporting obligations following its Nasdaq listing, with oversight provided by its board of directors and executive leadership team.

Key executives identified in recent public filings include:

• Bret Christensen – Chief Executive Officer
• Mark A. Pugh – Chairman
• Ryan P. Saxton – Chief Financial Officer
• Terri A. Ross – Chief Operating Officer
• Richard National – Chief Medical Officer

Leadership communications in investor presentations and regulatory filings consistently emphasize practitioner enablement, operational scalability, and long-term growth in personalized wellness and hormone optimization services.